Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amir Lahouegue

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Safety|July 12, 2023
Will the future of pharmacovigilance be more automated?Francesco Salvo, Joelle Micallef, Amir Lahouegue, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 27, 2017
The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological StudyBeverley Balkau, Bernard Charbonnel, Alfred Penfornis, et al.
Drugs - Real World Outcomes|April 13, 2026
First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in FranceLouis Marie Dourthe, Aline Guillot, Cécile Vassal, et al.
Drugs - Real World Outcomes|January 11, 2023
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data StudyCharlotte Bellier, Laurence Gladieff, Fanny Le Du, et al.
Therapie|December 26, 2022
What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?Antoine Pariente, Joëlle Micallef, Amir Lahouegue, et al.
Therapie|December 28, 2022
Antoine Pariente, Joëlle Micallef, Amir Lahouegue, et al.
Therapie|January 26, 2022
Prevention of risks associated with inappropriate use/unnecessary consumption of medicinesJean-Luc Cracowski, Sophie Muller, Isabelle Anglade, et al.
Therapie|January 24, 2022
Jean-Luc Cracowski, Sophie Muller, Isabelle Anglade, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Safety|July 12, 2023
Will the future of pharmacovigilance be more automated?Francesco Salvo, Joelle Micallef, Amir Lahouegue, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 27, 2017
The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological StudyBeverley Balkau, Bernard Charbonnel, Alfred Penfornis, et al.
Drugs - Real World Outcomes|April 13, 2026
First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in FranceLouis Marie Dourthe, Aline Guillot, Cécile Vassal, et al.
Drugs - Real World Outcomes|January 11, 2023
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data StudyCharlotte Bellier, Laurence Gladieff, Fanny Le Du, et al.
Therapie|December 26, 2022
What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?Antoine Pariente, Joëlle Micallef, Amir Lahouegue, et al.
Therapie|December 28, 2022
Antoine Pariente, Joëlle Micallef, Amir Lahouegue, et al.
Therapie|January 26, 2022
Prevention of risks associated with inappropriate use/unnecessary consumption of medicinesJean-Luc Cracowski, Sophie Muller, Isabelle Anglade, et al.
Therapie|January 24, 2022
Jean-Luc Cracowski, Sophie Muller, Isabelle Anglade, et al.
Pageof 1